NOXXON announces results of the extraordinary general meeting of shareholders
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targ…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Kre…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Kre…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treat…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), ein Biotechnologieunternehmen, das sich auf die Verbesserung von Kre…
NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treat…
NOXXON Pharma announced today the publication of a new study in Cell Reports, entitled "SDF-1 Inhibition Targets the Bon…
NOXXON Pharma announced today that one of its Spiegelmer® therapeutics, olaptesed pegol (NOX-A12), received orphan drug…